The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer

Radiotherapy and Oncology

Volumn 55, Issue 3, 2000, Pages 317-324

  Vanuytsel, Luc J ^a   Vansteenkiste, Johan F ^a   Stroobants, Sigrid G ^a   De Leyn, Paul R ^a   De Wever, Walter ^a   Verbeken, Eric K ^a   Gatti, Giovanna G ^a   Huyskens, Dominique P ^a   Kutcher, Gerald J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

18F fluoro 2 deoxy D glucose positron emission tomography; Lymph node; Non small cell lung cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DOSIMETRY; HISTOGRAM; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; LUNG TUMOR; LYMPH NODE; METHODOLOGY; PATHOLOGY; PROSPECTIVE STUDY; RADIATION DOSE; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034195192     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00138-9     Document Type: Article

References (20)

1. Chin R., Ward R., Keyes J.W., et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am. J. Respir. Crit. Care Med. 152:1995;2090-2096.
2. Dillemans B., Deneffe G., Verschakelen J., Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur. J. Cardio-thorac. Surg. 8:1994;37-42.
3. Galen P.S. Predictive values of laboratory tests. Am. J. Cardiol. 36:1975;536-538.
4. Graham M.V. Predicting radiation response. Int. J. Rad. Oncol. Biol. Phys. 39:1997;561-562.
5. Graham M.V., Purdy J.A. Regarding predicting radiation response. In response to Dr. Lawrence et al. (Letter to the editor). Int. J. Rad. Oncol. Biol. Phys. 41:1998;972-973.
6. Graham M.V., Purdy J.A., Emami B., et al. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int. J. Rad. Oncol. Biol. Phys. 33:1995;993-1000.
7. Kiffer J.D., Berlangieri S.U., Scot A.M., et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 19:1998;167-177.
8. Kwa S.L.S., Lebesque J.V., Theuws J.C.M., et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int. J. Rad. Oncol. Biol. Phys. 42:1998;1-9.
9. Marks L.B., Munley M.T., Bentel G.C., et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int. J. Rad. Oncol. Biol. Phys. 39:1997;563-570.
10. Martel M.K., Ten Haken R.K., Hazuka M., et al. B. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis, Int. J. Rad. Oncol. Biol. Phys. (28):1994;575-581.
11. Naruke T., Suemasu K., Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J. Thorac. Cardiovasc. Surg. 76:1978;832-837.
12. Patz E.F., Lowe V.J., Goodman P.C., et al. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. 108:1995;1617-1621.
13. Robertson J.M., Ten Haken R.K., Hazuka M.B., et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int. J. Rad. Oncol. Biol. Phys. 7:1997;1079-1085.
14. Sasaki M., lchiya Y., Kuwabara Y., et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur. J. Nucl. Med. 23:1996;741-747.
15. Sazon D.A.D., Santiago S.M., Hoo G.W.S., et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am. J. Respir. Crit. Care Med. 153:1996;417-421.
16. Valk P.E., Pounds T.R., Hopkins D.M., et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann. Thorac. Surg. 60:1995;1573-1582.
17. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. The Leuven lung cancer group, Ann. Thorac. Surg. 63:1997;1441-1450.
18. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J. Clin. Oncol. 16:1998;2141-2149.
19. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., et al. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? Eur. J. Nucl. Med. 25:1998;1495-1501.
20. Wahl R.L., Quint L.E., Greenough R.L., et al. Staging of mediastinal non-small cell lung cancer with FDG PET. CT, and fusion images: Preliminary prospective evaluation, Radiology. 191:1994;371-377.